Вы находитесь на странице: 1из 13

CHAPTER 52 

Systemic Anti-infective Therapy for


Periodontal Diseases
Sebastian G. Ciancio | Angelo J. Mariotti

CHAPTER OUTLINE
Definitions
Systemic Administration of Antibiotics
Serial and Combination Antibiotic Therapy
Conclusion

It is therefore logical to treat periodontal pockets by mechanically


Learning Objectives removing local factors (including the calculus that harbors bacteria)
• Evaluate the rationale for use of anti-infective agents as adjuncts and by disrupting the subgingival plaque biofilm itself. Mechanical
to periodontal therapy. removal includes manual instrumentation (e.g., scaling and root
• List the clinical indications for use of anti-infective agents. planing) and machine-driven instrumentation (e.g., ultrasonic scalers),
• Evaluate the pharmacology of anti-infective agents indicated as and these procedures can be considered “anti-infective therapy.”
adjuncts to periodontal therapy. Many chemotherapeutic agents are now available to clinicians who
treat periodontal diseases. Systemic anti-infective therapy (oral
antibiotics) and local anti-infective therapy (placing anti-infective
agents directly into the periodontal pocket) can reduce the bacterial
It has been well established that the various periodontal diseases challenge to the periodontium. It is also possible that systemically
are caused by bacterial infection. Bacteria begin reattaching to administered nonsteroidal antiinflammatory agents may play a role
tooth surfaces soon after the teeth have been cleaned and start in future adjunctive therapy.42,58
to form a biofilm. Over time, this supragingival plaque biofilm Bacteria and their toxic products may cause a loss of attach-
becomes more complex, which leads to a succession of bacteria ment and a loss of bone. Ultimately, however, the host’s own
that are more pathogenic. Bacteria grow in an apical direction and immunologic response to this bacterial infection can cause even
become subgingival. Eventually, as bone is destroyed, a periodon- more bone destruction (i.e., indirect bone loss) than that caused by
tal pocket is formed. In a periodontal pocket, the bacteria form a pathogenic bacteria and their by products. This immunologic response
highly structured and complex biofilm. As this process continues, can be influenced by environmental (e.g., tobacco use), acquired
the bacterial biofilm extends so far subgingivally that the patient (e.g., systemic disease), or genetic risk factors.49 Chemotherapeutic
cannot reach it during oral hygiene efforts. In addition, this complex agents can modulate the host’s immune response to bacteria and
biofilm may now offer some protection from the host’s immunologic reduce the host’s self-destructive immunologic response to bacte-
mechanisms in the periodontal pocket as well as from antibiotics rial pathogens, thereby reducing bone loss.45-47 It is also incumbent
used for treatment. It has been suggested that an antibiotic strength on health care providers to counsel patients about the detrimental
that is 500 times greater than the usual therapeutic dose may be effects of systemic factors, including medications, stress, and
needed to be effective against bacteria that have become arranged in tobacco use.26
biofilms.26 This chapter reviews the indications and protocols for optimizing
the use of systemically administered anti-infective agents during the
treatment of periodontal diseases. It is important to note that there has
Systemic Administration of Antibiotics been significant work with the use of a systematic evidence-based
Tetracyclines approach to evaluate the various anti-infective and host modulation
Metronidazole therapies.64 A meta-analysis of similar research studies has given
Penicillins power to statistical analysis to evaluate anti-infective chemotherapeutic
Cephalosporins agents for the treatment of periodontal disease. Unfortunately, a
Clindamycin standardized research protocol has not yet been implemented. As
Ciprofloxacin a result, some studies, although relevant, have not been used in
Macrolides the evidence-based approach because of their study design. Further
evidence-based and similar research is needed to define protocols

555
Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 555.e1

Abstract
This chapter provides information relative to the prescribing of
systemic antibiotics of value as adjuncts to periodontal therapy. The
systemic administration of antibiotics may be a necessary adjunct
for the control of bacterial infection because bacteria can invade
periodontal tissues, thereby sometimes making mechanical therapy
alone less effective. The clinical information in this chapter will
allow the practitioner to understand and know the indications,
contraindications, and protocols for optimizing the use of antibiotics
as part of the treatment of periodontal diseases. The prescribing
regimen for systemically administered antibiotics is usually by the
oral route of administration and depends on the mechanism of action,
patient’s health status and history, and clinical presentation. The
information in this chapter should provide guidance to clinicians
relative to the misuse of antibiotics, which has led to the emergence
of resistant microorganisms.

Keywords
anti-infective
antibiotics
systemic
periodontal diseases
resistance
periodontal pathogens
tetracyclines
penicillins
metronidazole
clindamycin
macrolides
combination therapy

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
556 Part 3  Clinical Periodontics

TABLE 52.1  Antibiotics Used to Treat Periodontal Diseases


Category Agent Major Features
a
Penicillin Amoxicillin Extended spectrum of antimicrobial activity; excellent oral absorption; used systemically
Augmentinb Effective against penicillinase-producing microorganisms; used systemically
Tetracyclines Minocycline Effective against a broad spectrum of microorganisms; used systemically and applied locally (subgingivally)
Doxycycline
Tetracycline Effective against a broad spectrum of microorganisms; used systemically and applied locally (subgingivally)
Chemotherapeutically used in subantimicrobial doses for host modulation (Periostat)
Effective against a broad spectrum of microorganisms
Quinolone Ciprofloxacin Effective against gram-negative rods; promotes health-associated microflora
Macrolide Azithromycin Concentrates at sites of inflammation; used systemically
Lincomycin derivative Clindamycin Used in penicillin-allergic patients; effective against anaerobic bacteria; used systemically
Nitroimidazolec Metronidazole Effective against anaerobic bacteria; used systemically and applied locally (subgingivally) as gel
a
Indications: localized aggressive periodontitis, generalized aggressive periodontitis, medically related periodontitis, and refractory periodontitis.
b
Amoxicillin and clavulanate potassium.
c
Indications: localized aggressive periodontitis, generalized aggressive periodontitis, medically related periodontitis, refractory periodontitis, and necrotizing ulcerative periodontitis.

more precisely for the use of anti-infective agents to treat various


periodontal diseases.
Systemic Administration of Antibiotics
Background and Rationale
The treatment of periodontal diseases is based on their infectious
KEY FACT nature (Table 52.1). Ideally, the causative microorganisms should
be identified, and the most effective agent should be selected with
Bacteriostatic Versus Bactericidal Antibiotics the use of antibiotic-sensitivity testing. Although this appears simple,
Pharmacologic agents that prevent the growth of bacteria are bacteriostatic the difficulty lies primarily in identifying the specific etiologic
antibiotics, whereas pharmacologic agents that actually kill the bacteria microorganisms rather than the microorganisms that are simply
are bactericidal antibiotics. Examples of bacteriostatic antibiotics include associated with various periodontal disorders.12
tetracycline and clindamycin, and penicillin and metronidazole are good An ideal antibiotic for use in the prevention and treatment of
examples of bactericidal antibiotics. periodontal disease should be specific for periodontal pathogens,
allogenic, nontoxic, substantive, not in general use for the treatment
of other diseases, and inexpensive.22 Currently, however, an ideal
antibiotic for the treatment of periodontal disease does not exist.32
Definitions Although oral bacteria are susceptible to many antibiotics, no single
An anti-infective agent is a chemotherapeutic agent that acts by antibiotic at the concentrations achieved in body fluids inhibits all
reducing the number of bacteria present. An antibiotic is a naturally putative periodontal pathogens.61 Indeed, a combination of antibiotics
occurring, semisynthetic, or synthetic type of anti-infective agent may be necessary to eliminate all putative pathogens from some
that destroys or inhibits the growth of select microorganisms, generally periodontal pockets43 (Table 52.2).
at low concentrations. An antiseptic is a chemical antimicrobial agent As always, the clinician, in concert with the patient, must make
that can be applied topically or subgingivally to mucous membranes, the final decision regarding any treatment. Thus the treatment of an
wounds, or intact dermal surfaces to destroy microorganisms and individual patient must be based on the patient’s clinical status, the
inhibit their reproduction or metabolism. In dentistry, antiseptics are nature of the colonizing bacteria, the ability of the agent to reach
widely used as the active ingredient in antiplaque and antigingivitis the site of infection, and the risks and benefits associated with the
oral rinses and dentifrices. Disinfectants (a subcategory of antiseptics) proposed treatment plan. The clinician is responsible for choosing
are antimicrobial agents that are generally applied to inanimate the correct antimicrobial agent. Some adverse reactions include
surfaces to destroy microorganisms.13 allergic or anaphylactic reactions, superinfections of opportunistic
When anti-infective agents are administered orally, many of these bacteria, development of resistant bacteria, interactions with other
agents can be found in the gingival crevicular fluid (GCF). The medications, upset stomach, nausea, and vomiting.3 Most adverse
purpose of a systemic administration of antibiotics is to reduce the reactions take the form of gastrointestinal upset.32 Other concerns
number of bacteria present in the diseased periodontal pocket; this include the cost of the medication and the patient’s willingness and
is often a necessary adjunct for controlling bacterial infection, because ability to comply with the proposed therapy.
bacteria can invade periodontal tissues, thereby making mechanical No consensus exists regarding the magnitude of risk for the
therapy alone sometimes ineffective.2,11,12,21,48 development of bacterial resistance. The common and indiscriminate
A single chemotherapeutic agent can also have a dual mechanism use of antibiotics worldwide has contributed to increasing numbers
of action. For example, tetracyclines (especially doxycycline) are of resistant bacterial strains since the late 1990s, and this trend is
chemotherapeutic agents that can reduce collagen and bone destruction likely to continue given the widespread use of antibiotics.10,18,62 The
via their ability to inhibit the enzyme collagenase. As antibiotic overuse, misuse, and widespread prophylactic application of anti-
agents, they can also reduce periodontal pathogens in periodontal infective drugs are some of the factors that have led to the emergence
tissues.12 of resistant microorganisms. Increasing levels of resistance of

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 557

subgingival microflora to antibiotics have been correlated with the


increased use of antibiotics in individual countries.10,57 However, Pharmacology
researchers have noted that the subgingival microflora tends to revert The tetracyclines are a group of antibiotics that are produced naturally
to similar proportions of antibiotic-resistant isolates 3 months after from certain species of Streptomyces or derived semisynthetically.
therapy.20,28 These antibiotics are bacteriostatic and are effective against rapidly
multiplying bacteria. They generally are more effective against gram-
Tetracyclines positive bacteria than against gram-negative bacteria. Tetracyclines
Tetracyclines have been widely used for the treatment of periodontal are effective for the treatment of periodontal diseases in part because
diseases. They have been frequently used to treat refractory peri- their concentration in the gingival crevice is 2 to 10 times that found
odontitis, including localized aggressive periodontitis (LAP)31,63 (see in serum.1,4,24 This allows a high drug concentration to be delivered
Table 52.1). Tetracyclines have the ability to concentrate in the into the periodontal pockets. In addition, several studies have
periodontal tissues and inhibit the growth of Aggregatibacter acti- demonstrated that tetracyclines at a low GCF concentration (i.e.,
nomycetemcomitans. In addition, tetracyclines exert an anticollagenase 2 µg/ml to 4 µg/ml) are very effective against many periodontal
effect that can inhibit tissue destruction and may help with bone pathogens.5,6
regeneration.9,37,60
Clinical Use
Tetracyclines have been investigated as adjuncts for the treatment
TABLE 52.2  Common Antibiotic Regimens Used to Treat of LAP.31,51 A. actinomycetemcomitans is a microorganism that is
Periodontal Diseasesa frequently associated with LAP, and it invades tissue. Therefore the
Regimen Dosage/Duration mechanical removal of calculus and plaque from root surfaces may
not eliminate this bacterium from the periodontal tissues. Systemic
Single Agent tetracycline can eliminate tissue bacteria and has been shown to
Amoxicillin 500 mg Three times daily for 8 days arrest bone loss and suppress A. actinomycetemcomitans levels in
Azithromycin 500 mg Once daily for 4 to 7 days conjunction with scaling and root planing.50 This combination therapy
allows for the mechanical removal of root surface deposits and the
Ciprofloxacin 500 mg Twice daily for 8 days
elimination of pathogenic bacteria from within the tissues.53 Increased
Clindamycin 300 mg Three times daily 10 days posttreatment bone levels have been noted with the use of this method
Doxycycline or 100 mg to 200 mg Once daily for 21 days (Figs. 52.1 to 52.4).
minocycline As a result of increased resistance to tetracyclines, metronidazole
or amoxicillin with metronidazole has been found to be more effective
Metronidazole 500 mg Three times daily for 8 days
for the treatment of aggressive periodontitis in children and young
Combination Therapy adults. Some investigators think that metronidazole in combination
Metronidazole + 250 mg of each Three times daily for 8 days with amoxicillin–clavulanic acid is the preferable antibiotic.59
amoxicillin Long-term use of low antibacterial doses of tetracyclines has
Metronidazole + 500 mg of each Twice daily for 8 days been advocated in the past. One long-term study of patients taking
ciprofloxacin low doses of tetracycline (i.e., 250 mg/day for 2 to 7 years) dem-
onstrated the persistence of deep pockets that did not bleed after
a
These regimens are prescribed after a review of the patient’s medical history, periodontal probing. These sites contained high proportions of tetracycline-
diagnosis, and antimicrobial testing. Clinicians must consult pharmacology references such resistant gram-negative rods (Fusobacterium nucleatum). After the
as Mosby’s GenRx41 or the manufacturer’s guidelines for warnings, contraindications, and
precautions.
antibiotic was discontinued, the flora was characteristic of sites with
Data from Jorgensen MG, Slots J: Practical antimicrobial periodontal therapy. Compend disease.32 Therefore it is not advisable to prescribe a long-term regimen
Contin Educ Dent 21:111, 2000. of tetracyclines because of the possible development of resistant

Fig. 52.1  Panoramic image of 17-year-old African American male exhibiting signs of localized aggressive
periodontitis. (Photo courtesy Dr. Sasi Sunkari.)

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
558 Part 3  Clinical Periodontics

Fig. 52.2  Image of anterior dentition in 17-year-old African American male with localized aggressive periodontitis.
(Photo courtesy Dr. Sasi Sunkari.)

Fig. 52.3  Preoperative radiograph of anterior mandible in localized Fig. 52.4  Postoperative radiograph of anterior mandible in localized
aggressive periodontitis patient. (Photo courtesy Dr. Sasi Sunkari.) aggressive periodontitis patient treated with a combination of antibiotic
therapy, scaling and root planing, and surgical intervention. (Photo courtesy
Dr. Sasi Sunkari.)

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 559

bacterial strains.34 Although tetracyclines were often used in the past organisms and is thought to disrupt bacterial DNA synthesis in
as anti-infective agents, especially for LAP and other types of conditions with a low reduction potential. Metronidazole is not the
aggressive periodontitis, they are now frequently replaced by more drug of choice for treating A. actinomycetemcomitans infections.
effective combination antibiotics.32 However, metronidazole is effective against A. actinomycetemcomitans
when used in combination with other antibiotics.43,44 Metronidazole
Specific Agents is also effective against anaerobes such as Porphyromonas gingivalis
Tetracycline, minocycline, and doxycycline are semisynthetic members and Prevotella intermedia.25
of the tetracycline group that have been used in periodontal therapy.
Clinical Use
Tetracycline Metronidazole has been used clinically to treat acute necrotizing
Treatment with tetracycline hydrochloride requires the administration ulcerative gingivitis, chronic periodontitis, and aggressive periodon-
of 250 mg four times daily. It is inexpensive, but compliance may titis. It has been used as monotherapy and also in combination with
be reduced by the need to take the medication so frequently. Side root planing and surgery or with other antibiotics. Metronidazole has
effects include gastrointestinal disturbances, photosensitivity, been used successfully to treat necrotizing ulcerative gingivitis.39
hypersensitivity, increased blood urea nitrogen levels, blood dyscrasias, Studies in humans have demonstrated the efficacy of metronidazole
dizziness, and headache. In addition, tooth discoloration occurs when for the treatment of periodontitis.38 A single dose of metronidazole
this drug is administered to children who are 12 years old or younger. (250 mg orally) appears in both serum and GCF in sufficient quantities
to inhibit a wide range of suspected periodontal pathogens. When
it is administered systemically (i.e., 750 mg/day to 1000 mg/day for
KEY FACT 2 weeks), metronidazole reduces the growth of anaerobic flora,
Tetracycline and Tooth Discoloration including spirochetes, and it decreases the clinical and histopathologic
Tetracycline has the ability to chelate with calcium and therefore gets signs of periodontitis.38 The most common regimen is 250 mg
deposited in mineralized tissues such as bone or teeth during the mineraliza- 3 times daily for 7 days.39 Currently, the critical level of spirochetes
tion process, resulting in yellow to brown discoloration of teeth. that is needed to diagnose an anaerobic infection, the appropriate
time to give metronidazole, and the ideal dosage or duration of
therapy are unknown.25 As monotherapy (i.e., with no concurrent
Minocycline root planing), metronidazole is inferior and at best only equivalent
Minocycline is effective against a broad spectrum of microorganisms. to root planing. Therefore if it is used, metronidazole should not be
In patients with adult periodontitis, it suppresses spirochetes and administered as monotherapy.
motile rods as effectively as scaling and root planing, with suppression Soder and colleagues52 demonstrated that metronidazole was more
evident up to 3 months after therapy. Minocycline can be given effective than placebo for the management of sites that were unre-
twice daily, thereby facilitating compliance as compared with tetra- sponsive to root planing. Nevertheless, many patients still had sites
cycline. Although it is associated with less phototoxicity and renal that bled with probing, despite metronidazole therapy. The existence
toxicity than tetracycline, minocycline may cause reversible vertigo. of refractory periodontitis as a diagnostic consideration indicates
Minocycline administered at a dose of 200 mg/day for 1 week results that some patients do not respond to conventional therapy, which
in a reduction of total bacterial counts, complete elimination of may include root planing, surgery, or both.
spirochetes for up to 2 months, and improvement of all clinical Studies have suggested that when it is combined with amoxicillin
parameters.13,14 or amoxicillin–clavulanate potassium (Augmentin), metronidazole
Side effects are similar to those of tetracycline; however, there may be of value for the management of patients with LAP or refractory
is an increased incidence of vertigo. It is the only tetracycline that periodontitis. This is discussed in more detail later in this chapter.
can permanently discolor erupted teeth and gingival tissue when
administered orally. Side Effects
Metronidazole has an Antabuse effect when alcohol is ingested. The
Doxycycline response is generally proportional to the amount ingested and can
Doxycycline has the same spectrum of activity as minocycline and result in severe cramps, nausea, and vomiting. Products that contain
can be equally effective.12 Because doxycycline can be given only alcohol should be avoided during therapy and for at least 1 day
once daily, patients may be more compliant. Compliance is also after therapy is discontinued. Metronidazole also inhibits warfarin
improved because its absorption from the gastrointestinal tract is metabolism. Patients who are undergoing anticoagulant therapy should
only slightly altered by calcium, metal ions, or antacids, as is absorp- avoid metronidazole, because it prolongs prothrombin time.39 It also
tion of other tetracyclines. Side effects are similar to those of tetra- should be avoided in patients who are taking lithium. This drug
cycline hydrochloride; however, it is the most photosensitizing agent produces a metallic taste in the mouth, which may affect compliance.
in the tetracycline category.
The recommended dosage when doxycycline is used as an anti- Penicillins
infective agent is 100 mg twice daily the first day, which is then Pharmacology
reduced to 100 mg daily. To reduce gastrointestinal upset, 50 mg Penicillins are the drugs of choice for the treatment of many serious
can be taken twice daily after the initial dose. When given as a infections in humans and are the most widely used antibiotics.
sub-antimicrobial dose (to inhibit collagenase), 20 mg of doxycycline Penicillins are natural and semisynthetic derivatives of broth cultures
twice daily is recommended.9,16 of the Penicillium mold. They inhibit bacterial cell wall production
and therefore are bactericidal.
Metronidazole
Pharmacology Clinical Use
Metronidazole is a nitroimidazole compound that was developed in Penicillins other than amoxicillin and amoxicillin–clavulanate potas-
France to treat protozoal infections. It is bactericidal to anaerobic sium (Augmentin) have not been shown to increase periodontal

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
560 Part 3  Clinical Periodontics

attachment levels, and their use in periodontal therapy does not colleagues62 showed that clindamycin helped stabilize refractory
appear to be justified. patients; the dosage used was 150 mg 4 times daily for 10 days.
Jorgensen and Slots33 recommend a regimen of 300 mg twice daily
Side Effects for 8 days.
Penicillins may induce allergic reactions and bacterial resistance.
Side Effects
Clindamycin has been associated with pseudomembranous colitis,
KEY FACT but the incidence is higher with cephalosporins and ampicillin. When
Penicillin Allergy needed, however, clindamycin can be used with caution, but it is
Up to 10% of patients may be allergic to penicillin. Reactions to ingestion not indicated for patients with a history of colitis. Diarrhea or cramping
of penicillin or its derivatives, such as amoxicillin, in allergic patients can that develops during clindamycin therapy may be indicative of colitis,
range from skin rash to life-threatening anaphylaxis. and it should be discontinued. If symptoms persist, the patient should
be referred to an internist.

Amoxicillin Ciprofloxacin
Amoxicillin is a semisynthetic penicillin with an extended anti- Pharmacology
infective spectrum that includes gram-positive and gram-negative Ciprofloxacin is a quinolone that is active against gram-negative
bacteria. It demonstrates excellent absorption after oral administration. rods, including all facultative and some anaerobic putative periodontal
Amoxicillin is susceptible to penicillinase, which is a β-lactamase pathogens.41
produced by certain bacteria that breaks the penicillin ring structure
and thus renders penicillins ineffective. Clinical Use
Amoxicillin may be useful for the management of patients with Because it demonstrates a minimal effect on Streptococcus species,
aggressive periodontitis in both localized and generalized forms. which are associated with periodontal health, ciprofloxacin therapy
The recommended dosage is 500 mg 3 times daily for 8 days.32,33 may facilitate the establishment of a microflora that is associated with
periodontal health. At present, ciprofloxacin is the only antibiotic
Amoxicillin–Clavulanate Potassium in periodontal therapy to which all strains of A. actinomycetem-
The combination of amoxicillin with clavulanate potassium makes comitans are susceptible. It has also been used in combination with
this anti-infective agent resistant to penicillinase enzymes produced metronidazole.43
by some bacteria. Amoxicillin with clavulanate (Augmentin) may
be useful for the management of patients with LAP or refractory Side Effects
periodontitis.42 Bueno and colleagues8 reported that Augmentin arrested Nausea, headache, metallic taste in the mouth, and abdominal discom-
alveolar bone loss in patients with periodontal disease that was fort have been associated with ciprofloxacin. Quinolones inhibit the
refractory to treatment with other antibiotics, including tetracycline, metabolism of theophylline, and caffeine and concurrent administration
metronidazole, and clindamycin. can produce toxicity. Quinolones have also been reported to enhance
the effects of warfarin and other anticoagulants.62
Cephalosporins
Pharmacology Macrolides
The family of β-lactams known as cephalosporins is similar in action Pharmacology
and structure to the penicillins. These drugs are frequently used in Macrolide antibiotics contain a many-membered lactone ring to which
medicine, and they are resistant to a number of β-lactamases that one or more deoxy sugars are attached. They inhibit protein synthesis
are normally active against penicillin. by binding to the 50S ribosomal subunits of sensitive microorganisms.
Macrolides can be bacteriostatic or bactericidal, depending on the
Clinical Use concentration of the drug and the nature of the microorganism. The
Cephalosporins are generally not used to treat dental-related infections. macrolide antibiotics used for periodontal treatment include eryth-
The penicillins are superior to cephalosporins with regard to their romycin, spiramycin, and azithromycin.
range of action against periodontal pathogenic bacteria.
Clinical Use
Side Effects Erythromycin does not concentrate in GCF and is not effective against
Patients who are allergic to penicillins must be considered to be most putative periodontal pathogens. For these reasons, erythromycin
allergic to all β-lactam products. More specifically, up to 10% of is not recommended as an adjunct to periodontal therapy.
patients who have an allergy to penicillin may also have an adverse Spiramycin is active against gram-positive organisms; it is excreted
reaction to cephalosporins. Rashes, urticaria, fever, and gastrointestinal in high concentrations in saliva. It is used as an adjunct to periodontal
upset have all been associated with cephalosporins.62 treatment in Canada and Europe but is not available in the United
States. Spiramycin has a minimal effect on attachment levels.
Clindamycin Azithromycin is a member of the azalide class of macrolides. It
Pharmacology is effective against anaerobes and gram-negative bacilli. After an
Clindamycin is effective against anaerobic bacteria and has a strong oral dosage of 500 mg 4 times daily for 3 days, significant levels
affinity for osseous tissue.56 It is effective for situations in which of azithromycin can be detected in most tissues for 7 to 10 days.7,30
the patient is allergic to penicillin. The concentration of azithromycin in tissue specimens from peri-
odontal lesions is significantly higher than that of normal gingiva.40
Clinical Use It has been proposed that azithromycin penetrates fibroblasts and
Clindamycin has demonstrated efficacy in patients with peri- phagocytes in concentrations that are 100 to 200 times greater than
odontitis that is refractory to tetracycline therapy. Walker and that of the extracellular compartment. Azithromycin is actively

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 561

transported to sites of inflammation by phagocytes, where it is released and ciprofloxacin targets facultative anaerobes. This is a powerful
directly into the sites of inflammation as the phagocytes rupture combination against mixed infections. Studies of this drug combination
during phagocytosis.23 Therapeutic use requires a single dose of for the treatment of refractory periodontitis have documented marked
250 mg/day for 5 days after an initial loading dose of 500 mg.62 clinical improvement. This combination may provide a therapeutic
Data have suggested that azithromycin may be an effective benefit by reducing or eliminating pathogenic organisms and a
adjunctive therapy for increasing attachment levels in patients with prophylactic benefit by giving rise to a predominantly streptococcal
aggressive periodontitis27 as well as for reducing the degree of gingival microflora.43
enlargement.15 These data must be carefully considered, because Systemic antibiotic therapy in combination with mechanical
they were derived from small subject populations. Currently, the therapy appears to be valuable for the treatment of recalcitrant
literature presents conflicting reports regarding the efficacy of this periodontal infections and LAP infections that involve A. actinomy-
antibiotic as an adjunct to periodontal therapy. One study concluded cetemcomitans. Antibiotic treatment should be reserved for specific
that adjunctive azithromycin provides no additional benefit over subsets of periodontal patients who do not respond to conventional
nonsurgical periodontal treatment for the parameters investigated in therapy. The selection of specific agents should be guided by the
patients with severe generalized chronic periodontitis. Furthermore, results of cultures and sensitivity tests for subgingival plaque
an additional study reported that there was an increase in cardiovas- microorganisms.
cular deaths among patients who received azithromycin; this increase
was most pronounced among patients with a high baseline risk of Pharmacologic Implications
cardiovascular disease. As a result of this study, the US Food and Principles of antibiotic therapy for the proper selection of an
Drug Administration issued a warning that the drug can alter the antibiotic minimally require identification of the causative organ-
electrical activity of the heart, which may lead to a potentially fatal ism, determination of the antibiotic sensitivity, and an effective
heart rhythm known as prolonged QT interval. This rhythm causes method of administration.29 The use of antibiotics to treat gingival
the timing of the heart’s contractions to become irregular. The warning diseases is contraindicated, because this is a local infection that
stated that physicians should use caution when giving the antibiotic can be easily treated with scaling and appropriate home care by
to patients who are known to have this condition or who are at risk the patient.54 With regard to destructive periodontal diseases, there
for cardiovascular problems. are limited data to support the use of systemic antibiotic treatment.
To ascertain the efficacy of azithromycin for the management of Although bacterial infections of the periodontium are considered to
periodontal diseases, future studies will need to increase the number be important to initiation of the disease, currently no one microbe
of subjects, improve diagnostic methods and tools, and determine or group of microbes has been demonstrated to be the cause of
the appropriate dose, duration, and frequency of azithromycin therapy. these diseases. It is therefore not surprising that systemic antibiotics
have had only a modest effect on the management of periodontal
diseases. At this time, systemic antibiotics for the treatment of
Serial and Combination Antibiotic Therapy periodontal diseases have been indicated primarily for adjunc-
Rationale tive use in the treatment of aggressive periodontal diseases26,28
Because periodontal infections may contain a wide variety of bacteria, (Table 52.3).
no single antibiotic is effective against all putative pathogens. Indeed, Guidelines for the use of antibiotics in periodontal therapy include
differences exist in the microbial flora associated with the various the following:
periodontal disease syndromes.63 These “mixed” infections can include 1. The clinical diagnosis and situation dictate the need for possible
a variety of aerobic, microaerophilic, and anaerobic bacteria, which antibiotic therapy as an adjunct for controlling active periodontal
may be both gram negative and gram positive. In these cases, it may disease (Fig. 52.5). The patient’s diagnosis can change over time.
be necessary to use more than one antibiotic, either serially or in For example, a patient who presents with generalized mild chronic
combination.44 Before combinations of antibiotics are used, however, periodontitis can return to a diagnosis of periodontal health after
the periodontal pathogens being treated should be identified and initial therapy. However, if the patient has been treated and
antibiotic-susceptibility testing performed.65 continues to have active disease, the diagnosis may change to
generalized severe chronic periodontitis.
Clinical Use 2. Disease activity as measured by continuing attachment loss,
Antibiotics that are bacteriostatic (e.g., tetracycline) generally require purulent exudate, and bleeding on probing35,36 may be an indication
rapidly dividing microorganisms to be effective. They do not function for periodontal intervention and possible microbial analysis through
well if a bactericidal antibiotic (e.g., amoxicillin) is given concurrently. plaque sampling.
When both types of drugs are required, they are best given serially 3. When they are used to treat periodontal disease, antibiotics are
rather than in combination. selected on the basis of the patient’s medical and dental status
Rams and Slots44 reviewed combination therapy involving the and current medications,32 and the results of microbial analysis,
use of systemic metronidazole along with amoxicillin, amoxicillin– if it is performed.
clavulanate (Augmentin), or ciprofloxacin. The metronidazole– 4. Microbiologic plaque sampling may be performed according to
amoxicillin and metronidazole–Augmentin combinations provided the instructions of the reference laboratory. The samples are usually
excellent elimination of many organisms in adults with LAP who taken at the beginning of an appointment, before instrumentation
had been treated unsuccessfully with tetracyclines and mechanical of the pocket. Supragingival plaque is removed, and an endodontic
debridement. These drugs have an additive effect that involves the paper point is inserted subgingivally into the deepest pockets to
suppression of A. actinomycetemcomitans. Tinoco and colleagues55 absorb bacteria in the loosely associated plaque. This endodontic
found metronidazole and amoxicillin to be clinically effective for point is placed in reduced transfer fluid or a sterile transfer tube
the treatment of LAP, although 50% of patients who were treated and sent to the laboratory. The laboratory will then send the
with this regimen harbored A. actinomycetemcomitans 1 year later. referring dentist a report that includes the pathogens that are
The metronidazole–ciprofloxacin combination is effective against present and any appropriate antibiotic regimen. At this time, there
A. actinomycetemcomitans; metronidazole targets obligate anaerobes, are scant data to suggest that microbial identification from a

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
562 Part 3  Clinical Periodontics

TABLE 52.3  Therapeutic Uses of Systemic Antimicrobial Agents for Various Periodontal Diseases
Adjunct or Stand-Alone
Disease Systemic Antimicrobial Agents Therapy
Gingival diseases Antibiotic use not recommended Not applicable
Necrotizing ulcerative gingivitis Antibiotic use not recommended unless there are systemic complications (e.g., As an adjunct when necessary
fever, swollen lymph nodes)
Chronic periodontitis Limited benefit; antibiotic use not recommended Not applicable
Aggressive periodontitis Antibiotic use recommended; for greatest benefit, therapeutic levels of As an adjunct
antibiotics should be achieved by the time scaling and root planing are
completed (all debridement should be completed within a week); the optimal
antibiotic type, dose, frequency, and duration have not been identified
Necrotizing ulcerative Antibiotic use dependent on the systemic condition of the patient As an adjunct when necessary
periodontitis
Periodontitis as a manifestation Antibiotic use dependent on the systemic condition of the patient As an adjunct when necessary
of systemic disease
Periodontal abscess Antibiotic use not recommended Not applicable

Clinical diagnosis
Aggressive periodontitis
Refractory cases
Periimplant disease
Periodontal abscess

Debridement–SRP

Host modulation plus


Resolution Nonresolution
local delivery

Surgery

Antibiotics

Local and
Local delivery Systemic antibiotics
systemic antibiotics

Resolution Resolution Nonresolution

Resolution Nonresolution Nonresolution Surgery

Surgery Systemic antibiotics Local delivery

Resolution Resolution Nonresolution

Nonresolution Surgery

Surgery

Fig. 52.5  A decision tree for the selection of antibiotic therapy.

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 563

plaque sample can be used to clinically improve the periodontal obtain a thorough medical history, including current medications
condition of the patient. and the possible adverse effects of combining these medicines, before
5. Meta-analyses of randomized clinical trials and quasi-experimental prescribing any antibiotic therapy. The clinician must make the final
studies have shown that systemic antibiotics can improve attach- decision with the patient. Risks and benefits concerning antibiotics
ment levels when they are used as adjuncts to scaling and root as adjuncts to periodontal therapy should be discussed with the patient
planing. The same benefits could not be demonstrated when before antibiotics are used.
antibiotics were used as a stand-alone therapy.28
6. When systemic antibiotics were used as adjuncts to scaling and
root planing, improvements were observed in the attachment Conclusion
levels of patients with chronic and aggressive periodontitis, Scaling and root planing alone are effective for reducing pocket
although patients with aggressive periodontitis experienced greater depths, gaining increases in periodontal attachment levels, and
benefits.28 The mean attachment level change depended on the decreasing inflammation levels (i.e., bleeding with probing). When
antibiotic used and ranged from 0.09 mm to 1.10 mm.28 systemic antibiotics are used as adjuncts to scaling and root planing,
7. The identification of which antibiotics were most effective for the evidence indicates that some systemic antibiotics (e.g., metro-
the treatment of destructive periodontal diseases was limited by nidazole, tetracycline) provide additional improvements in attachment
the insufficient sizes of the samples found in the randomized levels (0.35 mm for metronidazole; 0.40 mm for tetracycline) when
clinical trials used as part of a systematic review.28 A meta-analysis used as adjuncts to scaling and root planing.28 The use of anti-infective
evaluating eight different antibiotics or antibiotic combinations chemotherapeutic treatment adjuncts does not result in significant
showed that only tetracycline and metronidazole significantly adverse effects for patients.
improved attachment levels when they were used as adjuncts to The decision regarding when to use systemic antimicrobials should
scaling and root planing for patients with destructive periodontal be made on the basis of the clinician’s consideration of the clinical
diseases.28 findings, the patient’s medical and dental history,17,19 the patient’s
8. Debridement of root surfaces, optimal oral hygiene, and frequent preferences, and the potential benefits of adjunctive therapy with
periodontal maintenance therapy are important parts of compre- these agents.
hensive periodontal therapy. As mentioned previously, an antibiotic
strength that is 500 times greater than the systemic therapeutic
dose may be required to be effective against bacteria that have CHAPTER HIGHLIGHTS
been arranged into biofilm. It is therefore important to disrupt • The systemic administration of antibiotics may be a necessary
the biofilm physically so that the antibiotic agents can have access adjunct for controlling bacterial infection, because bacteria can
to the periodontal pathogens.26 invade periodontal tissues, thereby making mechanical therapy
9. Although there are adequate data to suggest that systemic alone sometimes ineffective.
antibiotics can be of benefit for the treatment of destructive • Although oral bacteria are susceptible to many antibiotics, no single
periodontal diseases, there are limited data available to identify antibiotic at the concentrations achieved in body fluids inhibits all
which antibiotics are suitable for which infection; the optimum putative periodontal pathogens.
dosage, frequency, and duration of antibiotic therapy; when the • The protocol for use of anti-infective agents depends on the
regimen should be introduced during the treatment schedule; the mechanism of action, the patient’s health status and history, and
long-term outcomes of antibiotic use; the potential hazards of these the clinical presentation.
agents (e.g., antibiotic resistance, changes in oral microflora)28;
and the economic ramifications of this type of pharmacologic
intervention. A Case Scenario is found on the companion website
The selection of an antibiotic must be made on the basis of factors www.expertconsult.com.
other than the empirical decisions made by the clinician. Unfortunately,
there is no one best choice of antibiotic at present (i.e., there is no
“silver bullet”). Therefore the clinician must integrate the history of References
the patient’s disease, the clinical signs and symptoms, and the results
of radiographic examinations and possibly microbiologic sampling References for this chapter are found on the companion
website www.expertconsult.com.
to determine the course of periodontal therapy. The clinician must

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 563.e1

CASE SCENARIO 52.1 


Patient:  27-year-old Caucasian female Current Findings:  Probing depths are in the range of 1 to 8 mm. The
deeper (>6 mm) probing depths are confined to maxillary incisors and
Chief Complaint:  “My gums bleed when I brush my teeth.”
first molars (Fig. A). Oral hygiene is optimal. Radiographically, vertical
Background Information defect is noted mesial to all first molars. A representative radiographic
The patient is a nonsmoker with no systemic medical conditions, but she vertical defect mesial to #19 is shown in Fig. B.
is allergic to penicillin. She reports that her sister, who is 32 years old,
has a similar gum condition. The patient says that she brushes twice a
day and flosses three or four times in a week.

A B

CASE-BASED QUESTIONS SOLUTION AND EXPLANATION


1. Based on the history and clinical presentation, what is the likely Answer: C
diagnosis? Explanation: Considering the patient’s age, family history, clinical
A. Chronic periodontitis presentation (severe attachment loss confined to first molars and
B. Acute necrotizing ulcerative gingivitis (ANUG) incisors in spite of good oral hygiene), and radiographic findings
C. Localized aggressive periodontitis (LAP) (vertical bone loss around first molars), a diagnosis of LAP can be
D. Necrotizing ulcerative periodontitis (NUP) made.
2. Can you prescribe a combination of amoxicillin and metronidazole Answer: B
for this patient while performing scaling and root planing? Explanation: This patient is allergic to penicillin, and because
A. Yes amoxicillin is a derivative of penicillin, it should not be given to a
B. No penicillin-allergic patient. In such cases, metronidazole can be given
alone or combined with other antibiotics, such as ciprofloxacin.
3. In North America, when compared with Caucasians, LAP is more Answer: A
prevalent in patients of African descent. Explanation: Several epidemiologic studies point to a higher prevalence
A. True of LAP (approximately 10 times more) in people of African descent
B. False when compared with Caucasians.

Images courtesy Dr. Kelsey Tengan.

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
563.e2 Part 3  Clinical Periodontics

26. Greenstein G: Changing periodontal concepts: treatment considerations,


References Compend Contin Educ Dent 26:81, 2005.
1. Alger FA, Solt CW, Vuddhankanok S, et al: The histologic evaluation 27. Haas AN, de Castro GD, Moreno T, et al: Azithromycin as an adjunctive
of new attachment in periodontally diseased human roots treated with treatment of aggressive periodontitis: 12-months randomized clinical
tetracycline hydrochloride and fibronectin, J Periodontol 61:447, 1990. trial, J Clin Periodontol 35:696, 2008.
2. American Academy of Periodontology, Research, Science and Therapy 28. Haffajee AD, Socransky SS, Gunsolley JC: Systemic anti-infective
Committee: Systemic antibiotics in periodontics, J Periodontol 75:1553, periodontal therapy: a systematic review, Ann Periodontol 8:115, 2003.
2004. 29. Hessen MT, Kaye D: Principles of use of antibacterial agents, Infect
3. American Dental Association, Council on Scientific Affairs: Combating Dis Clin North Am 18:435, 2004.
antibiotic resistance, J Am Dent Assoc 135:484, 2004. 30. Hoepelman IM, Schneider MM: Azithromycin: the first of the tissue-
4. Bader HI, Goldhaber P: The passage of intravenously administered selective azalides, Int J Antimicrob Agents 5:145, 1995.
tetracycline into the gingival sulcus of dogs, J Oral Ther Pharmacol 31. Jepsen K, Jepsen S: Antibiotics/antimicrobials: systemic and local
2:324, 1968. administration in the therapy of mild to moderately advanced periodontitis,
5. Baker PJ, Evans RT, Slots J, et al: Antibiotic susceptibility of anaerobic Periodontol 2000 71(1):82–112, 2016.
bacteria from the oral cavity, J Dent Res 65:1233, 1985. 32. Jorgensen MG, Slots J: Practical antimicrobial periodontal therapy,
6. Baker PJ, Evans RT, Slots J, et al: Susceptibility of human oral anaerobic Compend Contin Educ Dent 21:111, 2000.
bacteria to antibiotics suitable for topical use, J Clin Periodontol 12:201, 33. Jorgensen MG, Slots J: Responsible use of antimicrobials in periodontics,
1985. J Cal Dent Assoc 28:185, 2000.
7. Blandizzi C, Tecla M, Lupetti A, et al: Periodontal tissue disposition of 34. Kornman KS, Karl EH: The effect of long-term low-dose tetracycline
azithromycin in patients affected by chronic inflammatory periodontal therapy on the subgingival microflora in refractory adult periodontitis,
diseases, J Periodontol 70:960, 1999. J Periodontol 53:604, 1982.
8. Bueno L, Walker C, van Ness W, et al: Effect of Augmentin on microbiota 35. Lang NP, Adler R, Joss A, et al: The absence of bleeding on probing:
associated with refractory periodontitis, J Dent Res 67:246, 1988. an indicator of periodontal stability, J Clin Periodontol 17:7144, 1990.
9. Caton JG, Ciancio SG, Blieden TM, et al: Treatment with subantimicrobial 36. Lang NP, Joss A, Orsanic T, et al: Bleeding on probing: a predictor
dose doxycycline improves the efficacy of scaling and root planing in for the progression of periodontal disease?, J Clin Periodontol 13:590,
patients with adult periodontitis, J Periodontol 71:521, 2000. 1986.
10. Centers for Disease Control and Prevention, Antibiotic/antimicrobial 37. Lee HM, Ciancio SG, Tuter G, et al: Subantimicrobial dose doxycycline
resistance. https://www.cdc.gov/drugresistance/. efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis
11. Christersson LA, Slots J, Rosling BG, et al: Microbiological and clinical is enhanced when combined with a non-steroidal anti-inflammatory
effects of surgical treatment of localized juvenile periodontitis, J Clin drug, J Periodontol 75:453, 2004.
Periodontol 12:465, 1985. 38. Lekovic V, Kenney EB, Carranza FA, Jr, et al: Effect of metronidazole
12. Ciancio SG: Use of antibiotics in periodontal therapy. In Newman MG, on human periodontal disease: a clinical and microbiologic study, J
Goodman A, editors: Antibiotics in dentistry, Chicago, 1983, Quintessence. Periodontol 54:476, 1983.
13. Ciancio SG: Antiseptics and antibiotics as chemotherapeutic agents 39. Lozdan J, Sheiham A, Pearlman BA, et al: The use of nitroimidazine
for periodontitis management, Compend Contin Educ Dent 21:59, in the treatment of acute ulcerative gingivitis: a double-blind controlled
2000. trial, Br Dent J 130:294, 1971.
14. Ciancio SG, Slots J, Reynolds HS, et al: The effect of short-term admin- 40. Malizia T, Tejada MR, Ghelardi E, et al: Periodontal tissue disposition
istration of minocycline HCl administration on gingival inflammation of azithromycin, J Periodontol 68:1206, 1997.
and subgingival microflora, J Periodontol 53:57, 1982. 41. Mosby’s GenRx, ed 10, St Louis, 2001, Mosby.
15. Clementini M, Vittorini G, Crea A, et al: Efficacy of AZM therapy in 42. Offenbacher S, Braswell L, Loos A, et al: Effects of flurbiprophen on
patients with gingival overgrowth induced by cyclosporine A: a systematic the progression of periodontitis in Macaca mulatta, J Periodontal Res
review, BMC Oral Health 8:34, 2008. 22:473, 1987.
16. Crout R, Adams D, Blieden T, et al: Safety of doxycycline hyclate 20 mg 43. Rams TE, Feik D, Slots J: Ciprofloxacin/metronidazole treatment of
bid in patients with adult periodontitis. Presented at the annual meeting recurrent adult periodontitis, J Dent Res 71:319, 1992.
of the American Academy of Periodontology, Boston, 1998. 44. Rams TE, Slots J: Antibiotics in periodontal therapy: an update, Compend
17. Edelson H, Kaplan H, Korchak H: Differing effects of nonsteroidal Contin Educ Dent 13:1130, 1992.
anti-inflammatory agents on neutrophil functions, Clin Res 30:469A, 45. Reddy MS, Geurs NC, Gunsolley JC: Periodontal host modulation with
1982. antiproteinase, anti-inflammatory, and bone sparing agents: a systematic
18. Fairlamb AH, Gow NA, Matthews KR, et al: Drug resistance in eukaryotic review, Ann Periodontol 8:12, 2003.
microorganisms, Nat Microbiol 1(7):16092, 2016. 46. Research, Science and Therapy Committee: Pharmacologic blocking of
19. Feldman R, Szeto B, Chauncey H, et al: Nonsteroidal anti-inflammatory host responses as an adjunct in the management of periodontal diseases:
drugs in the reduction of human alveolar bone loss, J Clin Periodontol a research update, Chicago, 1992, American Academy of Periodontology.
10:131, 1983. 47. Rosling BG, Slots J, Christersson LA, et al: Topical antimicrobial therapy
20. Feres M, Haffajee AD, Allard K, et al: Antibiotic resistance of subgingival and diagnosis of subgingival bacteria in the management of inflammatory
species during and after periodontal therapy, J Clin Periodontol 28:12, periodontal disease, J Clin Periodontol 13:975, 1986.
2002. 48. Saglie FR, Carranza FA, Jr, Newman MG, et al: Identification of tissue
21. Genco RJ, Cianciola JJ, Rosling H: Treatment of localized juvenile invading bacteria in human periodontal disease, J Periodontal Res 17:452,
periodontitis, J Dent Res 60:527, 1981. 1982.
22. Gibson W: Antibiotics and periodontal disease: a selective review of 49. Salvi GE, Lawrence HP, Offenbacher S, et al: Influence of risk factors
the literature, J Am Dent Assoc 104:213, 1982. on the pathogenesis of periodontal disease, Periodontol 2000 14:173,
23. Gladue RP, Snyder ME: Intracellular accumulation of azithromycin 1997.
by cultured human fibroblasts, Antimicrob Agents Chemother 34:1056, 50. Slots J, Rams TE: Antibiotics and periodontal therapy: advantages and
1990. disadvantages, J Clin Periodontol 17:479, 1990.
24. Gordon JM, Walker CB, Murphy CJ, et al: Tetracycline: levels achievable 51. Slots J, Rosling BG: Suppression of periodontopathic microflora in local-
in gingival crevice fluid and in vitro effect on subgingival organisms. Part ized juvenile periodontitis by systemic tetracycline, J Clin Periodontol
I. Concentrations in crevicular fluid after repeated doses, J Periodontol 10:465, 1983.
52:609, 1981. 52. Soder P, Frithiof L, Wikner S, et al: The effects of systemic metronidazole
25. Greenstein G: The role of metronidazole in the treatment of periodontal after non-surgical treatment in moderate and advanced periodontitis in
diseases, J Periodontol 64:1, 1993. young adults, J Periodontol 61:281, 1990.

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CHAPTER 52  Systemic Anti-infective Therapy for Periodontal Diseases 563.e3

53. Stelzel M, Flores-De-Jacoby L: Topical metronidazole application 59. Walker C, Karpinia K: Rationale for use of antibiotics in periodontics,
compared with subgingival scaling: a clinical and microbiological study J Periodontol 73:1188, 2002.
on recall patients, J Clin Periodontol 23:24, 1996. 60. Walker C, Thomas J: The effect of subantimicrobial doses of doxycycline
54. Tatakis DN, Trombelli L: Modulation of clinical expression of plaque- on the microbial flora and antibiotic resistance in patients with adult
induced gingivitis. L. Background review and rationale, J Clin Periodontol periodontitis. Presented at the annual meeting of the American Academy
31:220, 2004. of Periodontology, Boston, 1998.
55. Tinoco EM, Beldi M, Campedelli F, et al: Clinical and microbiologic 61. Walker CB: The acquisition of resistance of antibiotic resistance in the
effects of adjunctive antibiotics in treatment of localized aggressive periodontal microflora, Periodontol 2000 10:79, 1996.
periodontitis: a controlled clinical study, J Periodontol 69:1355, 1998. 62. Walker CB: Selected antimicrobial agents: mechanisms of action, side
56. Tyler K, Walker CB, Gordon J, et al: Evaluation of clindamycin in effects and drug interactions, Periodontol 2000 10:12, 1996.
adult refractory periodontitis: antimicrobial susceptibilities, J Dent Res 63. Walker CB, Gordon JM, Magnusson I, et al: A role for antibiotics in
64:360, 1985. the treatment of refractory periodontitis, J Periodontol 64:772, 1993.
57. Van Winkelhoff AJ, Gonzales DH, Winkel EG, et al: Antimicrobial 64. Walker CB, Gordon JM, McQuilkin SJ, et al: Tetracycline: levels
resistance in the subgingival microflora in patients with adult periodontitis: achievable in gingival crevice fluid and in vitro effect on subgingival
a comparison between the Netherlands and Spain, J Clin Periodontol organisms. Part II. Susceptibilities of periodontal bacteria, J Periodontol
27:79, 2000. 52:613, 1981.
58. Waite I, Saxon C, Young A, et al: The periodontal status of subjects 65. Walker CB, Gordon JM, Socransky SS: Antibiotic susceptibility testing
receiving nonsteroidal anti-inflammatory drugs, J Periodontal Res 16:100, of subgingival plaque samples, J Clin Periodontol 10:422, 1983.
1981.

Downloaded for Evelyn Sarabia (evsarabiaay@uide.edu.ec) at International University of Ecuador from ClinicalKey.com by Elsevier on May 13, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.

Вам также может понравиться